These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25288766)

  • 1. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.
    Tajan M; Batut A; Cadoudal T; Deleruyelle S; Le Gonidec S; Saint Laurent C; Vomscheid M; Wanecq E; Tréguer K; De Rocca Serra-Nédélec A; Vinel C; Marques MA; Pozzo J; Kunduzova O; Salles JP; Tauber M; Raynal P; Cavé H; Edouard T; Valet P; Yart A
    Proc Natl Acad Sci U S A; 2014 Oct; 111(42):E4494-503. PubMed ID: 25288766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
    Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY
    BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
    Marin TM; Keith K; Davies B; Conner DA; Guha P; Kalaitzidis D; Wu X; Lauriol J; Wang B; Bauer M; Bronson R; Franchini KG; Neel BG; Kontaridis MI
    J Clin Invest; 2011 Mar; 121(3):1026-43. PubMed ID: 21339643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
    Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
    J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
    Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
    Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
    Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
    Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leopard syndrome.
    Sarkozy A; Digilio MC; Dallapiccola B
    Orphanet J Rare Dis; 2008 May; 3():13. PubMed ID: 18505544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
    Yi JS; Perla S; Enyenihi L; Bennett AM
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?
    Lauriol J; Kontaridis MI
    Trends Cardiovasc Med; 2011 May; 21(4):97-104. PubMed ID: 22681964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypical diversity of patients with LEOPARD syndrome carrying the worldwide recurrent p.Tyr279Cys PTPN11 mutation.
    Nemes E; Farkas K; Kocsis-Deák B; Drubi A; Sulák A; Tripolszki K; Dósa P; Ferenc L; Nagy N; Széll M
    Arch Dermatol Res; 2015 Dec; 307(10):891-5. PubMed ID: 26377839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
    Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
    Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
    Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LEOPARD syndrome: clinical diagnosis in the first year of life.
    Digilio MC; Sarkozy A; de Zorzi A; Pacileo G; Limongelli G; Mingarelli R; Calabrò R; Marino B; Dallapiccola B
    Am J Med Genet A; 2006 Apr; 140(7):740-6. PubMed ID: 16523510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome.
    Zhang J; Shen J; Cheng R; Ni C; Liang J; Li M; Yao Z
    Mol Med Rep; 2016 Sep; 14(3):2639-43. PubMed ID: 27484170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LEOPARD syndrome without hearing loss or pulmonary stenosis: a report of 2 cases.
    Ramos-Geldres TT; Dávila-Seijo P; Duat-Rodríguez A; Noguera-Morel L; Ezquieta-Zubicaray B; Rosón-López E; Hernández-Martín A; Torrelo-Fernández A
    Actas Dermosifiliogr; 2015 May; 106(4):e19-22. PubMed ID: 25544017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
    Paardekooper Overman J; Yi JS; Bonetti M; Soulsby M; Preisinger C; Stokes MP; Hui L; Silva JC; Overvoorde J; Giansanti P; Heck AJ; Kontaridis MI; den Hertog J; Bennett AM
    Mol Cell Biol; 2014 Aug; 34(15):2874-89. PubMed ID: 24865967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
    Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
    PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
    Jopling C; van Geemen D; den Hertog J
    PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
    Roy R; Krenz M
    J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.